CMS Sticks To Its Original Thinking In Final VAD Coverage Decision
This article was originally published in The Gray Sheet
Executive Summary
The agency’s Oct. 31 national coverage determination for ventricular assist devices differs little from the August proposal – a result that analysts are speculating could benefit VAD maker Thoratec and potentially disadvantage HeartWare.
You may also be interested in...
CMS Fields Many Suggestions And Criticisms On Proposed VAD Policy
Several stakeholders are still pushing CMS to recognize “bridge-to-decision” heart failure patients who may eventually be suitable for a heart transplant but are not so at the time they receive a ventricular assist device.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.